COVID-19: Study finds neutralising antibodies to disappear rapidlyA new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination. more ➔
BioVersys gets €20m EIB loan to develop novel antibioticsSwiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contractC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
